To further explore the therapeutic potential of mIL12 in combination with these inhibitors, we employed the MC38 tumor-bearing model to assess the antitumor efficacy of mIL12 combined with PD-1 inhibitors versus monotherapy (Figure 4A). Here, PDCD1 is linked to neoplasm.